Related Experiment Video
Updated: May 15, 2026

Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform
Published on: April 12, 2021
Major influence of renal function on hyperlipidemia after living donor liver transplantation
1Key Lab of Combined Multi-Organ Transplantation, Key Lab of Organ Transplantation, Ministry of Public Health, Hangzhou 310003, Zhejiang Province, China.
Insights
Post-transplant hyperlipidemia (PTHL) is common after liver transplants. Impaired renal function, particularly early renal dysfunction, significantly increases the risk of developing PTHL in these patients.
Area of Science:
- Hepatology
- Nephrology
- Cardiology
Background:
- Post-transplant hyperlipidemia (PTHL) is a frequent complication following liver transplantation.
- Understanding risk factors for PTHL is crucial for patient management and improving outcomes.
Purpose of the Study:
- To investigate the association between renal function and graft function with the development of PTHL.
- To identify risk factors for PTHL in adult patients undergoing living donor liver transplantation (LDLT).
Main Methods:
- Retrospective analysis of 115 adult LDLT recipients from January 2007 to May 2009.
- PTHL defined as specific lipid levels or pharmacologic treatment at 6 months post-transplant.
- Early renal dysfunction (ERD) defined by elevated creatinine or need for renal replacement therapy in the first week.
Main Results:
- The incidence of PTHL was 24.3% among the studied cohort.
- PTHL was associated with a higher incidence of post-transplant cardiovascular events.
- Serum creatinine positively correlated with triglycerides; ERD and BMI were independent risk factors for PTHL.
Conclusions:
- Renal function is a significant factor in the development of PTHL after LDLT.
- Post-transplant renal dysfunction, often stemming from pre-transplant renal insufficiency, contributes to PTHL.
- Early identification and management of renal dysfunction may help prevent PTHL.
Aim:
To investigate the impact of renal and graft function on post-transplant hyperlipidemia (PTHL) in living donor liver transplantation (LDLT).
Methods:
A total of 115 adult patients undergoing LDLT from January 2007 to May 2009 at a single center were enrolled. Data were collected and analyzed by the China Liver Transplant Registry retrospectively. PTHL was defined as serum triglycerides ≥ 150 mg/dL or serum cholesterol ≥ 200 mg/dL or the need for pharmacologic treatment at the sixth month after LDLT. Early renal dysfunction (ERD) was defined as serum creatinine ≥ 2 mg/dL and/or the need for renal replacement therapy in the first post-transplant week.
Results:
In 115 eligible patients, the incidence of PTHL was 24.3%. Recipients with PTHL showed a higher incidence of post-transplant cardiovascular events compared to those without PTHL (17.9% vs 4.6%, P = 0.037). Serum creatinine showed significant positive correlations with total serum triglycerides, both at post-transplant month 1 and 3 (P < 0.01). Patients with ERD had much higher pre-transplant serum creatinine levels (P < 0.001) and longer duration of pre-transplant renal insufficiency (P < 0.001) than those without ERD. Pre-transplant serum creatinine, graft-to-recipient weight ratio, graft volume/standard liver volume ratio, body mass index (BMI) and ERD were identified as risk factors for PTHL by univariate analysis. Furthermore, ERD [odds ratio (OR) = 9.593, P < 0.001] and BMI (OR = 6.358, P = 0.002) were identified as independent risk factors for PTHL by multivariate analysis.
Conclusion:
Renal function is closely associated with the development of PTHL in LDLT. Post-transplant renal dysfunction, which mainly results from pre-transplant renal insufficiency, contributes to PTHL.
Related Concept Videos
Kidney Transplant I: Introduction
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Kidney Transplant II: Surgical Procedure
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
Kidney Transplant III: Nursing Management
